A 36-Month study on the costutility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy

Journal of Asthma

Volumn 49, Issue 8, 2012, Pages 843-848

  Dal Negro, Roberto Walter ^a,b   Tognella, Silvia ^a   Pradelli, Lorenzo ^c  

^a Orlandi General Hospital   (Italy)

^b CESFAR   (Italy)

^c AdRes Health Economics and Outcomes Research   (Italy)

Author keywords

Cost utility; Difficult to treat atopic asthma; Effectiveness; Healthcare costs; Omalizumab

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; IMMUNOGLOBULIN E; OMALIZUMAB; XANTHINE DERIVATIVE;

ADD ON THERAPY; ADULT; ALLERGIC ASTHMA; ARTICLE; CLINICAL ARTICLE; COST UTILITY ANALYSIS; DRUG COST; FEMALE; GENERAL PRACTITIONER; HEALTH CARE COST; HEALTH STATUS; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; ITALY; LONG TERM CARE; LUNG FUNCTION; MALE; QUALITY OF LIFE; TREATMENT DURATION;

ADULT; ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; COHORT STUDIES; COST-BENEFIT ANALYSIS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; IMMUNOGLOBULIN E; ITALY; MALE; MIDDLE AGED; QUALITY OF LIFE;

EID: 84866354219     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.3109/02770903.2012.717659     Document Type: Article

References (25)

1. Bousquet J, Dahl R, Khaltaev N. Global alliance against chronic respiratory diseases. Eur Respir J 2007; 29:233-239.
2. Adcock IM, Caramori G, Chung KF. New targets for drug development in asthma. Lancet 2008; 372:1073-1087.
3. Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH. Anti-IgE for chronic asthma in adults and children (Cochrane Review). The Cochrane Library Issue. Vol 2. Chichester: Wiley, 2005.
4. FDA Omalizumab Product Approval Information Sheet 20-06-2003.
5. Niven R, Chung KF, Panahloo Z, Blogg M, Ayre G. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: An open-label study. Respir Med 2008; 102: 1371-1378.
6. Solèr M, Matz J, Townley R, Buhl R, O'Brien J, Fox H, Thirlwell J, Gupta N, Della Cioppa G. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18:254-261.
7. Busse WW. Anti-immunoglobulin E (omalizumab) therapy in allergic asthma. Am J Respir Crit Care Med 2001; 164:S12-S17.
8. Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecock S, Blogg M, Fox H, Surrey K. Efficacy and tolerability of antiimmunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004; 59:709-717.
9. Diukanovic R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF, Bao W, Fowler-Taylor A, Matthews J, Busse WW, Holgate ST, Fahy JV. Effects of treatment with anti-immunoglobulin E antibody omalizumab on irway inflammation in allergic asthma. Am J Respir Crit Care Med 2004; 170:583-593.
10. Ayers JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004; 59: 701-708.
11. Holgate ST, Chuchalin AG, Hébert J, Lötvall J, Persson GB, Chung KF, Bousquet J, Kerstjens HA, Fox H, Thirlwell J, Cioppa GD. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004; 34:632-638.
12. Humbert M, Beasley R, Ayers J, Slavin R, Hébert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S, Fox H, Blogg M, Surrey K. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60:309-316.
13. Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J, Rosen KE, Eisner MD, Wong DA, Busse W. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: A randomized trial. Ann Intern Med 2011; 154(9):573-582.
14. Dal Negro RW, Pradelli L, Tognella S, Micheletto C, Iannazzo S. Costutility of add-on omalizumab in difficult-to-treat allergic asthma in Italy. Eur Ann Allergy Clin Immunol. 2011; 43(2):45-53
15. Tognella S, Dal Negro RW. Omalizumab: Una risposta terapeuticogestionale per il controllo dell'asma grave resistente. It J Chest Dis 2007; 61:390-394.
16. Regional DRG Tariffs. Aggiornamento del tariffario per la remunerazione delle prestazioni di assistenza Ospedaliera. Regione Veneto. Deliberazione della Giunta n. 916 del 28-03-2006.
17. Regional Specialist Tariffs. Nomenclatore Tariffario Regionale delle prestazioni di assistenza specialistica ambulatoriale: Aggiornamento tariffe di cui alla D.G.R. n.61 del 21-01-05. Regione Veneto. Deliberazione della Giunta n. 917 del 28-03-2006.
18. Garattini L, Castelnuovo E, Lanzeni D, Viscarra C. Durata e costo delle visite in medicina generale: Il progetto DYSCO. Farmeconomia e percorsi terapeutici 2003; 4(2):109-114.
19. Italian Drugs Formulary. Informatore Farmaceutico - 68a edizione 2008. Elsevier Masson, 2008.
20. Off-Patent Drugs Reference Price System. Lista di trasparenza dei medicinali inseriti nell'elenco dei farmaci equivalenti (Legge 178/ 2002) con i relativi prezzi di riferimento aggiornati a giugno 2011. Available at: http://www.agenziafarmaco.gov.it/it/content/liste-ditrasparenza- e-rimborsabilita. Accessed September, 2011.
21. National Hospital Discharge Database. Statistiche sui ricoveri ospedalieri. Available at: http://www.ministerosalute.it/programmazione/sdo/ ric-informazioni/default.jsp. Accessed December, 2008.
22. Ståhl E, Lindberg A, Jansson SA, Rönmark E, Svensson K, Andersson F, Löfdahl CG, Lundbäck B.Health-related quality of life is related to COPD disease severity. Health Qual Life Outcomes 2005; 3:56.
23. Oba Y. Cost-effectiveness of long-acting bronchodilators for chronic obstructive pulmonary disease. Mayo Clin Proc 2007; 82(5): 575-582.
24. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: In search of a standard. Med Decis Making 2000; 20(3):332-342.
25. Bousquet J, Wenzel S, Holgate S, Lumry W, Freeman P, Fox H. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest 2004; 125(4):1378-1386.